CCDC110

Summary

CCDC110 (coiled-coil domain containing 110, HGNC:28504) is a protein-coding gene on chromosome 4q35.1, encoding Coiled-coil domain-containing protein 110 (Q8TBZ0).

Located in cytosol and nucleoplasm.

Source: NCBI Gene 256309 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 123 total — 2 likely-pathogenic
• Phenotypes (HPO): 3
• MANE Select transcript: NM_152775

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28504
Approved symbol	CCDC110
Name	coiled-coil domain containing 110
Location	4q35.1
Locus type	gene with protein product
Status	Approved
Aliases	KM-HN-1, MGC33607, CT52
Ensembl gene	ENSG00000168491
Ensembl biotype	protein_coding
OMIM	609488
Entrez	256309

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 7 protein_coding, 3 nonsense_mediated_decay

ENST00000307588, ENST00000393540, ENST00000504020, ENST00000506876, ENST00000506962, ENST00000507501, ENST00000508538, ENST00000510481, ENST00000510617, ENST00000651260

RefSeq mRNA: 2 — MANE Select: NM_152775 NM_001145411, NM_152775

CCDS: CCDS3843, CCDS47170

Canonical transcript exons

ENST00000307588 — 7 exons

Exon	Start	End
ENSE00001170150	185458126	185460238
ENSE00001199097	185445182	185445542
ENSE00001199119	185471674	185471733
ENSE00001199132	185470945	185471049
ENSE00003552800	185462994	185463049
ENSE00003648987	185462643	185462708
ENSE00003759725	185461049	185461159

Expression profiles

Bgee: expression breadth ubiquitous, 162 present calls, max score 97.75.

FANTOM5 (CAGE): breadth broad, TPM avg 0.7335 / max 102.8629, expressed in 327 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
55257	0.6281	313
55259	0.0689	9
55258	0.0272	4
55260	0.0093	4

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	97.75	gold quality
left testis	UBERON:0004533	94.48	gold quality
right testis	UBERON:0004534	93.58	gold quality
testis	UBERON:0000473	91.94	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.98	gold quality
body of pancreas	UBERON:0001150	87.15	gold quality
right uterine tube	UBERON:0001302	83.64	gold quality
pancreas	UBERON:0001264	83.63	gold quality
islet of Langerhans	UBERON:0000006	81.69	gold quality
adult organism	UBERON:0007023	81.25	gold quality
calcaneal tendon	UBERON:0003701	76.92	gold quality
right lobe of thyroid gland	UBERON:0001119	72.55	gold quality
adenohypophysis	UBERON:0002196	72.53	gold quality
left lobe of thyroid gland	UBERON:0001120	71.98	gold quality
right coronary artery	UBERON:0001625	71.24	gold quality
tibial artery	UBERON:0007610	71.18	gold quality
popliteal artery	UBERON:0002250	71.17	gold quality
thyroid gland	UBERON:0002046	70.80	gold quality
mucosa of stomach	UBERON:0001199	70.50	gold quality
pituitary gland	UBERON:0000007	70.12	gold quality
muscle of leg	UBERON:0001383	69.61	gold quality
gastrocnemius	UBERON:0001388	69.37	gold quality
aorta	UBERON:0000947	69.34	gold quality
hindlimb stylopod muscle	UBERON:0004252	69.17	gold quality
body of stomach	UBERON:0001161	68.88	gold quality
smooth muscle tissue	UBERON:0001135	68.80	gold quality
descending thoracic aorta	UBERON:0002345	68.75	gold quality
cerebellar hemisphere	UBERON:0002245	68.62	gold quality
cerebellar cortex	UBERON:0002129	68.51	gold quality
left coronary artery	UBERON:0001626	68.24	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.29

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

22 targeting CCDC110, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-1252-3P	99.55	67.71	2862
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-6088	99.29	68.45	1284
HSA-MIR-6780B-3P	99.13	67.18	622
HSA-MIR-153-3P	98.96	72.51	1644
HSA-MIR-7977	98.65	66.18	2590
HSA-MIR-4290	98.51	65.17	907
HSA-MIR-4766-3P	98.48	67.94	1347
HSA-MIR-937-5P	97.43	68.39	667
HSA-MIR-5000-5P	97.40	66.11	1055
HSA-MIR-6736-3P	96.98	65.22	1342
HSA-MIR-668-5P	90.24	59.97	79

Literature-anchored findings (GeneRIF, showing 1)

• KM-HN-1 is a novel human cancer/testis antigen recognized by cellular and humoral immune responses (PMID:15447989)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Coiled-coil domain-containing protein 110 — Q8TBZ0 (reviewed: Q8TBZ0)

Alternative names: Cancer/testis antigen 52, Cancer/testis antigen KM-HN-1

All UniProt accessions (9): Q8TBZ0, A0A096LNP5, A0A096LNZ5, A0A494C037, D6RB18, D6RCR3, D6RDN4, E7EUS2, H0Y9S3

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Nucleus.

Tissue specificity. Expressed specifically in testis. Also expressed in tumors of different origins.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8TBZ0-1	1	yes
Q8TBZ0-2	2

RefSeq proteins (2): NP_001138883, NP_689988* (*=MANE)

Domains & families (InterPro)

UniProt features (13 total): sequence variant 9, chain 1, coiled-coil region 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TBZ0-F1	66.67	0.31

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 609

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 29 (showing top): chr4q35, MIKKELSEN_IPS_HCP_WITH_H3_UNMETHYLATED, MIKKELSEN_ES_HCP_WITH_H3_UNMETHYLATED, MIKKELSEN_MEF_HCP_WITH_H3_UNMETHYLATED, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, GSE13522_CTRL_VS_T_CRUZI_BRAZIL_STRAIN_INF_SKIN_UP, METTL14_TARGET_GENES, ZNF423_TARGET_GENES, MIR4778_3P, MIR7977, GSE11057_NAIVE_VS_EFF_MEMORY_CD4_TCELL_UP, MIR143_3P_MIR4770, GSE11057_EFF_MEM_VS_CENT_MEM_CD4_TCELL_DN, MIR6088, MIR6748_5P

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): nucleoplasm (GO:0005654), cytosol (GO:0005829), cytoskeleton (GO:0005856), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
binding	1
nuclear lumen	1
cytoplasm	1
intracellular membraneless organelle	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

394 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCDC110	ZNF165	P49910	623
CCDC110	SPACA3	Q8IXA5	544
CCDC110	RBM46	Q8TBY0	507
CCDC110	CPXCR1	Q8N123	476
CCDC110	FAM149A	A5PLN7	475
CCDC110	FATE1	Q969F0	447
CCDC110	TRIML1	Q8N9V2	433
CCDC110	SPATA19	Q7Z5L4	422
CCDC110	MED14	O60244	419
CCDC110	MORC1	Q86VD1	400
CCDC110	CT47A11	Q5JQC4	399
CCDC110	CFAP96	A7E2U8	397
CCDC110	CCDC83	Q8IWF9	392
CCDC110	FTHL17	Q9BXU8	387
CCDC110	IGSF11	Q5DX21	384

IntAct

11 interactions, top by confidence:

A	B	Type	Score
DEPTOR	CCDC110	psi-mi:“MI:0915”(physical association)	0.560
CCDC110	FADS2	psi-mi:“MI:0915”(physical association)	0.400
CCDC110	SF3B2	psi-mi:“MI:0915”(physical association)	0.400
CCDC110	TGFBRAP1	psi-mi:“MI:0915”(physical association)	0.400
CCDC110	CFTR	psi-mi:“MI:0915”(physical association)	0.370
CAND1	GTPBP10	psi-mi:“MI:0914”(association)	0.350
CUL3	PXDNL	psi-mi:“MI:0914”(association)	0.350
CCDC110	addA	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): CCDC110 (Two-hybrid), XDH (Affinity Capture-MS), CCDC110 (Proximity Label-MS), CCDC110 (Proximity Label-MS), TGFBRAP1 (Affinity Capture-MS), CCDC110 (PCA), HIST1H4A (Cross-Linking-MS (XL-MS)), CCDC110 (Cross-Linking-MS (XL-MS)), CCDC110 (Cross-Linking-MS (XL-MS)), CCDC110 (Cross-Linking-MS (XL-MS)), CCDC110 (Cross-Linking-MS (XL-MS)), EEA1 (Cross-Linking-MS (XL-MS)), KPNA1 (Cross-Linking-MS (XL-MS)), PRPF6 (Cross-Linking-MS (XL-MS)), LINC00675 (Affinity Capture-RNA)

ESM2 similar proteins: A2AKX3, A2RUR9, A6NGH7, A9JSR5, A9ZSY0, E1BC15, O14513, O60284, P70347, Q19UN5, Q2M2Z5, Q2YDE5, Q32L17, Q3MJ40, Q3V089, Q3V125, Q49A88, Q4UJ75, Q569L8, Q5BQN8, Q5CZ79, Q5IR70, Q5RHB5, Q5SQ80, Q5TYW2, Q5VUR7, Q641I1, Q66HB6, Q6AXY9, Q6ZP01, Q7T005, Q7Z333, Q811D2, Q8CDM4, Q8IYA2, Q8K389, Q8TBZ0, Q8TC20, Q92628, Q95JR0

Diamond homologs: Q3V125, Q8TBZ0, Q95JS9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

123 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	2
Uncertain significance	108
Likely benign	8
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
442364	GRCh37/hg19 4q35.1-35.2(chr4:186349585-190957473)x1	Likely pathogenic
545305	Single allele	Likely pathogenic

SpliceAI

1275 predictions. Top by Δscore:

Variant	Effect	Δscore
4:185460239:C:CC	acceptor_gain	1.0000
4:185460891:CACAT:C	donor_gain	1.0000
4:185460895:T:C	donor_gain	1.0000
4:185460895:T:TA	donor_gain	1.0000
4:185461045:ATA:A	donor_loss	1.0000
4:185461046:T:TG	donor_loss	1.0000
4:185461047:A:AC	donor_gain	1.0000
4:185461047:AC:A	donor_loss	1.0000
4:185461048:C:CC	donor_gain	1.0000
4:185461048:C:CT	donor_loss	1.0000
4:185461051:AAT:A	donor_gain	1.0000
4:185462642:CCATG:C	donor_gain	1.0000
4:185462709:C:CC	acceptor_gain	1.0000
4:185462709:CTATG:C	acceptor_loss	1.0000
4:185471668:TCTTA:T	donor_loss	1.0000
4:185471669:CTTAC:C	donor_loss	1.0000
4:185471670:TTAC:T	donor_loss	1.0000
4:185471671:TACCC:T	donor_loss	1.0000
4:185471672:A:AC	donor_gain	1.0000
4:185471672:A:T	donor_loss	1.0000
4:185471672:AC:A	donor_gain	1.0000
4:185471673:C:CC	donor_gain	1.0000
4:185471673:C:CT	donor_loss	1.0000
4:185471673:CC:C	donor_gain	1.0000
4:185452239:T:A	donor_gain	0.9900
4:185460235:TAGG:T	acceptor_gain	0.9900
4:185460236:AGGC:A	acceptor_loss	0.9900
4:185460237:GG:G	acceptor_gain	0.9900
4:185460237:GGC:G	acceptor_loss	0.9900
4:185460239:C:CG	acceptor_loss	0.9900

AlphaMissense

5633 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:185462682:A:C	F66L	0.986
4:185462682:A:T	F66L	0.986
4:185462684:A:G	F66L	0.986
4:185461146:A:G	I84T	0.985
4:185461146:A:C	I84S	0.983
4:185462671:C:G	R70P	0.982
4:185458540:C:G	A683P	0.975
4:185462704:A:G	L59P	0.975
4:185458422:A:G	L722P	0.970
4:185461134:A:G	L88S	0.969
4:185459223:A:G	L455P	0.968
4:185461153:A:G	S82P	0.968
4:185461137:A:G	I87T	0.967
4:185462678:C:G	A68P	0.967
4:185462683:A:G	F66S	0.964
4:185458371:A:G	L739P	0.963
4:185461137:A:T	I87K	0.960
4:185462692:A:G	L63S	0.960
4:185462650:A:T	V77D	0.958
4:185458434:A:G	L718P	0.957
4:185459181:A:G	L469P	0.957
4:185458301:A:C	F762L	0.956
4:185458301:A:T	F762L	0.956
4:185458303:A:G	F762L	0.956
4:185462674:A:G	L69S	0.956
4:185458528:C:G	A687P	0.953
4:185462687:A:G	S65P	0.953
4:185459283:A:G	L435P	0.952
4:185461146:A:T	I84N	0.947
4:185461137:A:C	I87R	0.946

dbSNP variants (sampled 300 via entrez): RS1000005558 (4:185463452 T>C), RS1000028038 (4:185450704 A>G), RS1000275747 (4:185469267 T>G), RS10004061 (4:185467834 T>G), RS1000528250 (4:185450519 C>T), RS1000586835 (4:185445918 C>T), RS1000608136 (4:185468972 C>T), RS1000787840 (4:185469183 G>A), RS1000952180 (4:185450814 TG>T), RS10009945 (4:185450825 A>G), RS1001008312 (4:185464992 A>T), RS1001445207 (4:185464356 C>T), RS1001625633 (4:185447574 A>G), RS1001730974 (4:185466714 T>C,G), RS1001835209 (4:185454420 G>C)

Disease associations

OMIM: gene MIM:609488 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (3): dilated cardiomyopathy (MONDO:0005021), hypertrophic cardiomyopathy (MONDO:0005045), autism (MONDO:0005260)

Orphanet (2): Rare hypertrophic cardiomyopathy (Orphanet:217569), Dilated cardiomyopathy (Orphanet:217604)

HPO phenotypes

3 total (3 of 3 shown, HPO-id order):

HPO	Term
HP:0001644	Dilated cardiomyopathy
HP:0001639	Hypertrophic cardiomyopathy
HP:0000717	Autism

GWAS associations

0 associations (top):

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750
D002312	Cardiomyopathy, Hypertrophic	C14.280.238.100; C14.280.484.048.750.070.160

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sotorasib	affects cotreatment, decreases expression	1
methylmercuric chloride	decreases expression	1
bisphenol A	affects cotreatment, decreases methylation	1
trichostatin A	decreases expression, increases expression	1
sodium arsenite	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
trametinib	affects cotreatment, decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Benzo(a)pyrene	affects methylation	1
Cannabidiol	affects cotreatment, decreases expression	1
Cuprizone	affects cotreatment, decreases expression	1
Estradiol	increases expression	1
Melphalan	decreases expression	1
Oxygen	increases expression	1
Valproic Acid	increases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	increases methylation	1

Clinical trials (associated diseases)

284 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00374465	PHASE4	UNKNOWN	Therapy With Verapamil or Carvedilol in Chronic Heart Failure
NCT01293903	PHASE4	COMPLETED	Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy
NCT01557140	PHASE4	COMPLETED	A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
NCT01917149	PHASE4	COMPLETED	Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy
NCT02115581	PHASE4	COMPLETED	Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
NCT06236022	PHASE4	RECRUITING	The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
NCT00879060	PHASE4	COMPLETED	Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
NCT01721967	PHASE4	COMPLETED	Ranolazine for the Treatment of Chest Pain in HCM Patients
NCT02948998	PHASE4	UNKNOWN	Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
NCT03249272	PHASE4	TERMINATED	Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
NCT04133532	PHASE4	COMPLETED	Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy
NCT06401343	PHASE4	RECRUITING	Use of SGLT2i in noHCM With HFpEF
NCT07103655	PHASE4	NOT_YET_RECRUITING	The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
NCT07600177	PHASE4	RECRUITING	Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT00333827	PHASE3	COMPLETED	Cell Therapy In Dilated Cardiomyopathy
NCT00505154	PHASE3	COMPLETED	Effect of Rosuvastatin on Left Ventricular Remodeling
NCT01223703	PHASE3	COMPLETED	PUFAs and Left Ventricular Function in Heart Failure
NCT01583114	PHASE3	TERMINATED	PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors
NCT01914081	PHASE3	UNKNOWN	Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside
NCT02989181	PHASE3	UNKNOWN	Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea
NCT03439514	PHASE3	TERMINATED	A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT05849766	PHASE3	COMPLETED	Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
NCT06250257	PHASE3	RECRUITING	Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
NCT00317967	PHASE3	COMPLETED	Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart
NCT00698074	PHASE3	UNKNOWN	Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy
NCT00821353	PHASE3	COMPLETED	Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
NCT02431221	PHASE3	WITHDRAWN	Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure
NCT03470545	PHASE3	COMPLETED	Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT05174416	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
NCT05182658	PHASE3	ACTIVE_NOT_RECRUITING	Empagliflozin in Hypertrophic Cardiomyopathy
NCT05186818	PHASE3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
NCT05767346	PHASE3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT06116968	PHASE3	COMPLETED	An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
NCT06873828	PHASE3	NOT_YET_RECRUITING	Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
NCT07021976	PHASE3	RECRUITING	A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT07023341	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07202897	PHASE3	NOT_YET_RECRUITING	LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
NCT00629018	PHASE2	COMPLETED	Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
NCT00629096	PHASE2	COMPLETED	Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy